Inspira Technologies (IINN) announced that a top U.S. hospital, has expanded its clinical use of the INSPIRA ART100 system to lung transplantation procedures. Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, stated: “The decision by one of the most decorated and respected medical institutions in the United States to broaden the use of our ART100 system into lung transplantation is a highly meaningful step for Inspira. It reflects the growing confidence leading hospitals are placing in our technology and underscores its potential to become an essential platform in advanced respiratory care. This expansion marks an important step toward establishing the ART100 as part of the standard of care in the most complex surgical settings.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IINN:
- Inspira Technologies Secures U.S. Patent for ART500, Aiming to Dominate $20 Billion Market
- Inspira Technologies receives U.S. patent approval for ART500 technology
- Inspira Technologies Secures $27 Million Order for ART100 Systems
- Inspira secures $27M government binding purchase order for ART100 systems
- Inspira Technologies files $75M mixed securities shelf